SEATTLE -- Availability of a bevacizumab (Avastin) biosimilar for ophthalmic use could have the unintended consequence of driving up the cost of treating retinal disease with angiogenesis inhibitors, ...
The Agency is now requiring the submission of confirmatory efficacy data to support the application. The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Outlook ...
CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety of off-label indications and add hundreds of millions of dollars ...
A Prescription Drug User Fee Act target date of July 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License ...
On August 30, 2022, Outlook Therapeutics, Inc. announced that it has re-submitted its Biologics License Application (BLA) to the FDA for ONS-5010, “an investigational ophthalmic therapy which, if ...
Outlook Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) for ONS-5010 / LYTENAVA (bevacizumab-vikg), an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results